BNP Paribas Financial Markets Acquires 39,919 Shares of argenex SE $ARGX

BNP Paribas Financial Markets grew its stake in shares of argenex SE (NASDAQ:ARGX) by 59.8% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 106,714 shares of the company’s stock after purchasing an additional 39,919 shares during the period. BNP Paribas Financial Markets owned about 0.17% of argenex worth $78,708,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of ARGX. AQR Capital Management LLC boosted its position in shares of argenex by 32.1% during the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after buying an additional 122 shares during the last quarter. NewEdge Advisors LLC lifted its stake in argenex by 5,962.5% during the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after acquiring an additional 1,431 shares in the last quarter. Focus Partners Wealth boosted its holdings in argenex by 22.3% during the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after acquiring an additional 73 shares during the last quarter. Geneos Wealth Management Inc. grew its stake in shares of argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after acquiring an additional 99 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. bought a new stake in shares of argenex in the 2nd quarter worth $367,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on ARGX shares. Robert W. Baird boosted their price target on shares of argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a “hold” rating to a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. boosted their target price on argenex from $925.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. Morgan Stanley increased their price target on argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a research report on Thursday, December 4th. Finally, Wolfe Research reiterated a “peer perform” rating on shares of argenex in a report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $999.22.

argenex Stock Down 2.6%

Shares of ARGX stock opened at $708.85 on Friday. The firm has a market cap of $43.86 billion, a P/E ratio of 36.31, a PEG ratio of 1.20 and a beta of 0.38. The company has a 50 day moving average of $806.79 and a 200-day moving average of $815.81. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 26th. The company reported $8.02 EPS for the quarter, beating the consensus estimate of $6.05 by $1.97. argenex had a return on equity of 38.51% and a net margin of 30.42%.The business had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. As a group, equities analysts expect that argenex SE will post 3.13 EPS for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.